Ikeda Atsuki, Hoshi Namiko, Yoshizaki Tetsuya, Fujishima Yoshimi, Ishida Tsukasa, Morita Yoshinori, Ejima Yasuo, Toyonaga Takashi, Kakechi Yoshihiro, Yokosaki Hiroshi, Azuma Takeshi
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Intern Med. 2015;54(22):2803-13. doi: 10.2169/internalmedicine.54.3591. Epub 2015 Nov 15.
The standard treatment for submucosal esophageal cancer is esophagectomy or chemoradiotherapy (CRT). However, these treatment modalities could deteriorate the general condition and quality of life of the patients who are intolerant to invasive therapy. It is therefore important and beneficial to develop less invasive treatment protocols for these patients.
The study included 43 patients who were clinically suspected of mucosa or submucosal esophageal cancer but underwent endoscopic submucosal dissection (ESD) as a primary treatment, due to the patients' poor performance statuses and/or preferences for less invasive therapy. According to the pathological findings and patient's general condition, whether the patient underwent additional treatments or remained hospitalized without additional treatments was thereafter decided for each patient. We retrospectively analyzed the outcomes of these patients.
Fifteen patients underwent additional surgery, 11 patients underwent CRT/radiation therapy (RT) and 17 patients were followed without additional treatments. During the 3-year follow-up period, the relapse-free survival rates in the patients who received or did not receive additional treatments were 88% and 64%, respectively (95% confidence interval, 0.45-0.76, p=0.04). The relapse-free and overall survival rates in the patients with additional treatments were equivalent or superior to those described in previous reports of the standard treatments. Preceding ESD contributed to reduce the local relapse significantly to approximately 3.5% and additional CRT-related toxicities.
Preceding ESD is very effective for the local control of cancer, and useful for histologically confirming the high-risk factors of relapse, such as ≥submucosal layer 2 (SM2) invasion and lymphovascular involvements. ESD with additional therapy may be a promising strategy for optimizing the selection of therapy depending on the patient's general condition.
黏膜下食管癌的标准治疗方法是食管切除术或放化疗(CRT)。然而,这些治疗方式可能会使不耐受侵入性治疗的患者的一般状况和生活质量恶化。因此,为这些患者制定侵入性较小的治疗方案既重要又有益。
该研究纳入了43例临床上疑似患有黏膜或黏膜下食管癌但因患者身体状况较差和/或倾向于选择侵入性较小的治疗而接受内镜黏膜下剥离术(ESD)作为主要治疗的患者。根据病理结果和患者的一般状况,随后为每位患者决定是否接受额外治疗或在不接受额外治疗的情况下住院观察。我们回顾性分析了这些患者的治疗结果。
15例患者接受了额外的手术,11例患者接受了CRT/放射治疗(RT),17例患者未接受额外治疗而进行随访。在3年的随访期内,接受或未接受额外治疗的患者的无复发生存率分别为88%和64%(95%置信区间,0.45 - 0.76,p = 0.04)。接受额外治疗的患者的无复发生存率和总生存率与先前标准治疗报告中描述的相当或更高。先行ESD有助于将局部复发率显著降低至约3.5%,并减少与CRT相关的毒性。
先行ESD对癌症的局部控制非常有效,并且有助于从组织学上确认复发的高危因素,如黏膜下层2(SM2)及以上浸润和脉管侵犯。ESD联合额外治疗可能是一种根据患者一般状况优化治疗选择的有前景的策略。